Rosetta Genomics (Rosetta Genomics) Total Equity : $1.10 Mil (As of Jun. 2017)

View and export this data going back to 2007. Start your Free Trial

What is Rosetta Genomics Total Equity?

Rosetta Genomics's total equity for the quarter that ended in Jun. 2017 was $1.10 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Rosetta Genomics Total Equity Historical Data

The historical data trend for Rosetta Genomics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rosetta Genomics Total Equity Chart

Rosetta Genomics Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Total Equity

Get a 7-Day Free Trial

30.90

23.63

15.07

19.62

4.42

Rosetta Genomics Quarterly Data
	Dec10	Mar11	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Jun17
Total Equity	Get a 7-Day Free Trial															15.81	12.65	8.92	4.42	1.10

Rosetta Genomics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Rosetta Genomics's Total Equity for the fiscal year that ended in Dec. 2016 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2016 )	-	Total Liabilities(Q: Dec. 2016 )
	=	11.961	-	7.544
	=	4.42

Rosetta Genomics's Total Equity for the quarter that ended in Jun. 2017 is calculated as

Total Equity	=	Total Assets(Q: Jun. 2017 )	-	Total Liabilities(Q: Jun. 2017 )
	=	6.207	-	5.108
	=	1.10

Rosetta Genomics Total Equity Related Terms

Thank you for viewing the detailed overview of Rosetta Genomics's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Rosetta Genomics (Rosetta Genomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (OTCPK:ROSGQ) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 Plaut Street, Science Park, Rehovot, ISR, 76706

Website

http://www.rosettagenomics.com

Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.

Executives

Sabby Management, Llc	10 percent owner	115 HIDDEN HILLS DR, SPICEWOOD TX 78669
Sabby Healthcare Volatility Master Fund, Ltd.	10 percent owner	C/O SABBY MANAGEMENT, LLC, 10 MOUNTAINVIEW ROAD, SUITE 205, UPPER SADDLE RIVER NJ 07458

Rosetta Genomics (Rosetta Genomics) Headlines

From GuruFocus

Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS

By gurufocus • 12-09-2008